Actinium Pharmaceuticals Announces Inducement Grants to New Employees

Vesting of every award requires the executive to remain in service through the applicable vesting date.

Rhea-AI Summary

Actinium Pharmaceuticals (ATNM) granted inducement equity awards to its newly appointed chief financial officer and senior vice president of business development.

CFO Matt David received options for 250,000 shares at $0.97 on October 14, 2026, plus 250,000 restricted stock units (RSUs) and up to 75,000 milestone-based RSUs. Business development executive Sean Maenpaa received options for 40,000 shares at $1.06 on October 12, 2026, plus 20,000 RSUs and 50,000 RSUs subject to corporate milestones. Both options have ten-year terms, with exercise prices equal to the respective grant-date closing share prices. The awards were granted outside the 2019 Stock Plan under the 2026 Employment Inducement Award Plan.

Positive

• None.

Negative

• Minor point. Forward-looking: it has not happened yet and may not happen.Matt David's options for 250,000 shares at $0.97 create potential dilution upon exercise.
• Minor point. Forward-looking: it has not happened yet and may not happen.Matt David's 250,000 RSUs and up to 75,000 milestone-based RSUs create potential dilution upon vesting.
• Minor point. Forward-looking: it has not happened yet and may not happen.Sean Maenpaa's options for 40,000 shares at $1.06 create potential dilution upon exercise.
• Minor point. Forward-looking: it has not happened yet and may not happen.Sean Maenpaa's 20,000 RSUs and 50,000 milestone-conditioned RSUs create potential dilution upon vesting.

News Explained

The granted awards vest over time rather than immediately: both options vest 28% on the first anniversary and 2% monthly for the next 36 months; Matt David’s non-milestone RSUs vest in annual installments and at the third anniversary, while Sean Maenpaa’s vest annually. All awards require continued service through each vesting date, and milestone RSUs also depend on specified corporate milestones.

Key Figures

David stock option: 250,000 shares David option exercise price: $0.97 per share David restricted stock units: 250,000 RSUs +5 more

David stock option

250,000 shares

Granted October 14, 2026

David option exercise price

$0.97 per share

Option granted October 14, 2026

David restricted stock units

250,000 RSUs

Time-based vesting

David milestone-based RSUs

Up to 75,000 RSUs

Vesting upon specified corporate milestones

Maenpaa stock option

40,000 shares

Granted October 12, 2026

Maenpaa option exercise price

$1.06 per share

Option granted October 12, 2026

Maenpaa time-based RSUs

20,000 RSUs

Vest in three equal annual installments

Maenpaa milestone-based RSUs

50,000 RSUs

Vest subject to corporate milestones

Key Terms

non-qualified stock option, restricted stock units

2 terms

non-qualified stock option financial

"a non-qualified stock option to purchase 250,000 shares"

A non-qualified stock option (NSO) is a contract that lets an employee or service provider buy company shares at a fixed price for a set period, like a voucher to purchase stock later at today’s price. It matters to investors because exercising NSOs creates ordinary income for the holder and can increase share count, affecting a company’s earnings and ownership mix; think of it as a future sale that can dilute existing shareholders and has immediate tax consequences for the recipient.

restricted stock units financial

"granted 250,000 restricted stock units"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

NEW YORK, Oct. 16, 2026 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) ("Actinium" or the "Company"), a pioneer in the development of targeted radiotherapies, today announced inducement equity awards to Matt David, M.D., the Company's newly appointed Chief Financial Officer, and Sean Maenpaa, the Company's newly appointed Senior Vice President, Business Development.

In connection with Dr. David's appointment, on October 14, 2026 the Company granted Dr. David a non-qualified stock option to purchase 250,000 shares of the Company's common stock at an exercise price of $0.97 per share, equal to the closing price of Actinium's common stock on the NYSE American on October 14, 2026. The option has a ten-year term; 28% of the shares underlying the option vest on the first anniversary of the grant date, and the remainder vest in equal monthly installments of 2% of the shares underlying the option over the following 36 months. Dr. David was also granted 250,000 restricted stock units ("RSUs"), of which 125,000 vest in three equal annual installments on the first, second and third anniversaries of the grant date and 125,000 vest in full on the third anniversary of the grant date, as well as up to 75,000 RSUs that vest upon the achievement of specified corporate milestones.

In connection with Mr. Maenpaa's appointment, on October 12, 2026 the Company granted Mr. Maenpaa a non-qualified stock option to purchase 40,000 shares of the Company's common stock at an exercise price of $1.06 per share, equal to the closing price of Actinium's common stock on the NYSE American on October 12, 2026. The option has a ten-year term; 28% of the shares underlying the option vest on the first anniversary of the grant date, and the remainder vest in equal monthly installments of 2% of the shares underlying the option over the following 36 months. Mr. Maenpaa was also granted 20,000 RSUs that vest in three equal annual installments on the first, second and third anniversaries of the grant date, and 50,000 RSUs that vest on the third anniversary of the grant date, subject to the fulfillment of certain corporate milestones.

Vesting of each award is subject to the executive's continued service with the Company through the applicable vesting date. The awards were granted outside of the Company's Amended and Restated 2019 Stock Plan as an inducement material to each executive's entering into employment with the Company in accordance with Section 711(a) of the NYSE American Company Guide, and are subject to the terms of the Actinium Pharmaceuticals, Inc. 2026 Employment Inducement Award Plan and the applicable award agreements.

About Actinium Pharmaceuticals, Inc.

Actinium is a pioneer in targeted radiotherapies designed to improve outcomes for patients with cancer. The company employs a biology-driven approach to develop differentiated radiopharmaceuticals for solid tumors and hematologic malignancies. Its mission is to transform cancer treatment through innovative radioconjugates that maximize therapeutic efficacy while minimizing toxicity to healthy tissue by combining expertise in tumor biology, translational medicine, and radiochemistry. Since inception, Actinium has focused on developing innovative radiotherapies. Its pipeline reflects this strategy across three areas: (1) solid tumor therapeutics including ATNM-400 and Actimab-A with pan-tumor potential; (2) Actimab-A as a therapeutic backbone for acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) in collaboration with the National Cancer Institute (NCI); and (3) targeted conditioning agents including Iomab-B for bone marrow transplant and Iomab-ACT for cell and gene therapy conditioning. ATNM-400 targets a novel antigen distinct from PSMA and has demonstrated preclinical activity across metastatic castration-resistant prostate cancer (mCRPC), non-small cell lung cancer (NSCLC), and breast cancer, and is being evaluated in a first-in-human Phase 1 study in mCRPC. Actimab-A has shown improved survival in relapsed/refractory AML with CLAG-M and is advancing toward a Phase 2/3 trial, with additional development ongoing through a CRADA with the NCI. Actinium is also advancing preclinical solid tumor programs and holds ~250 patents and patent applications, including intellectual property related to cyclotron-based production of Ac-225. For more information, please visit www.actiniumpharma.com.

Forward-Looking Statements

This press release may contain projections or other "forward-looking statements" within the meaning of the "safe-harbor" provisions of the private securities litigation reform act of 1995 regarding future events or the future financial performance of the Company which the Company undertakes no obligation to update. These statements are based on management's current expectations and are subject to risks and uncertainties that may cause actual results to differ materially from the anticipated or estimated future results, including the risks and uncertainties associated with the Company's ability to retain key personnel, the Company's ability to obtain additional financing on acceptable terms or at all, the conduct, timing and results of the Company's clinical trials, estimates of potential markets for drugs under development, clinical trials, actions by the FDA and other governmental agencies, regulatory clearances, responses to regulatory matters, the market demand for and acceptance of Actinium's products and services, performance of clinical research organizations and other risks detailed from time to time in Actinium's filings with the Securities and Exchange Commission (the "SEC"), including without limitation its most recent annual report on form 10-K, subsequent quarterly reports on Forms 10-Q and Forms 8-K, each as amended and supplemented from time to time.

Investors: investorrelations@actiniumpharma.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/actinium-pharmaceuticals-announces-inducement-grants-to-new-employees-302911600.html

SOURCE Actinium Pharmaceuticals, Inc.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How do the Actinium ATNM inducement stock options vest?

Both executives' options vest 28% on the first anniversary of their respective grant dates, followed by equal monthly installments of 2% of the underlying shares over the following 36 months. Each option has a ten-year term. Vesting requires continued service through each applicable vesting date.

When do Matt David's and Sean Maenpaa's Actinium inducement RSUs vest?

David's 250,000 RSUs comprise 125,000 vesting in three equal annual installments and 125,000 vesting on the third grant anniversary; up to 75,000 additional RSUs vest upon specified corporate milestones. Maenpaa's 20,000 RSUs vest in three equal annual installments, while 50,000 vest on the third grant anniversary subject to corporate milestones. All vesting requires continued service.